{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:53:26Z","timestamp":1790643206028,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00125-024-06273-7","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T17:07:32Z","timestamp":1726247252000},"page":"2678-2690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional study"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9942-8263","authenticated-orcid":false,"given":"Astrid","family":"Lavens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0679-3203","authenticated-orcid":false,"given":"Christophe","family":"De Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-0303","authenticated-orcid":false,"given":"Philippe","family":"Oriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2326-4108","authenticated-orcid":false,"given":"Laurent","family":"Crenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4131-6936","authenticated-orcid":false,"given":"Jean-Christophe","family":"Philips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Vandenbroucke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0195-3060","authenticated-orcid":false,"given":"An-Sofie","family":"Vanherwegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8058-8734","authenticated-orcid":false,"given":"Frank","family":"Nobels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4055-5233","authenticated-orcid":false,"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the IQED Group of Experts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"issue":"25","key":"6273_CR1","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","volume":"353","author":"DM Nathan","year":"2005","unstructured":"Nathan DM, Cleary PA, Backlund J-YC et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353(25):2643\u20132653. https:\/\/doi.org\/10.1056\/NEJMoa052187","journal-title":"N Engl J Med"},{"issue":"14","key":"6273_CR2","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"DM Nathan","year":"1993","unstructured":"DCCT Research Group, Nathan DM, Genuth S et al (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14):977\u2013986. https:\/\/doi.org\/10.1056\/NEJM199309303291401","journal-title":"N Engl J Med"},{"issue":"5","key":"6273_CR3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2337\/dc15-1990","volume":"39","author":"Diabetes Control and Complications Trial (DCCT)\/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group","year":"2016","unstructured":"Diabetes Control and Complications Trial (DCCT)\/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT\/EDIC study 30-year follow-up. Diabetes Care 39(5):686\u2013693. https:\/\/doi.org\/10.2337\/dc15-1990","journal-title":"Diabetes Care"},{"issue":"11","key":"6273_CR4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(21)00246-1","volume":"9","author":"B Van der Schueren","year":"2021","unstructured":"Van der Schueren B, Ellis D, Faradji RN, Al-Ozairi E, Rosen J, Mathieu C (2021) Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol 9(11):776\u2013785. https:\/\/doi.org\/10.1016\/S2213-8587(21)00246-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"6273_CR5","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.2337\/dc18-1446","volume":"42","author":"J Edqvist","year":"2019","unstructured":"Edqvist J, Rawshani A, Adiels M et al (2019) BMI, mortality, and cardiovascular outcomes in type 1 diabetes: findings against an obesity paradox. Diabetes Care 42(7):1297\u20131304. https:\/\/doi.org\/10.2337\/dc18-1446","journal-title":"Diabetes Care"},{"issue":"2","key":"6273_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.metabol.2013.10.002","volume":"63","author":"JJ Chillar\u00f3n","year":"2014","unstructured":"Chillar\u00f3n JJ, Flores Le-Roux JA, Benaiges D, Pedro-Botet J (2014) Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism 63(2):181\u2013187. https:\/\/doi.org\/10.1016\/j.metabol.2013.10.002","journal-title":"Metabolism"},{"issue":"8","key":"6273_CR7","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3390\/jcm10081798","volume":"10","author":"C Colom","year":"2021","unstructured":"Colom C, Rull A, Sanchez-Quesada JL, P\u00e9rez A (2021) Cardiovascular disease in type 1 diabetes mellitus: epidemiology and management of cardiovascular risk. J Clin Med 10(8):1798. https:\/\/doi.org\/10.3390\/jcm10081798","journal-title":"J Clin Med"},{"issue":"12","key":"6273_CR8","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.2337\/dc16-2523","volume":"40","author":"JQ Purnell","year":"2017","unstructured":"Purnell JQ, Braffett BH, Zinman B et al (2017) Impact of excessive weight gain on cardiovascular outcomes in type 1 diabetes: results from the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) study. Diabetes Care 40(12):1756\u20131762. https:\/\/doi.org\/10.2337\/dc16-2523","journal-title":"Diabetes Care"},{"issue":"3","key":"6273_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2337\/dc06-1982","volume":"30","author":"ES Kilpatrick","year":"2007","unstructured":"Kilpatrick ES, Rigby AS, Atkin SL (2007) Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: \u2018double diabetes\u2019 in the Diabetes Control and Complications Trial. Diabetes Care 30(3):707\u2013712. https:\/\/doi.org\/10.2337\/dc06-1982","journal-title":"Diabetes Care"},{"issue":"2","key":"6273_CR10","doi-asserted-by":"publisher","first-page":"e14376","DOI":"10.1111\/dme.14376","volume":"38","author":"AS Lee","year":"2021","unstructured":"Lee AS, Twigg SM, Flack JR (2021) Metabolic syndrome in type 1 diabetes and its association with diabetes complications. Diabet Med 38(2):e14376. https:\/\/doi.org\/10.1111\/dme.14376","journal-title":"Diabet Med"},{"issue":"5","key":"6273_CR11","doi-asserted-by":"publisher","first-page":"e14529","DOI":"10.1111\/dme.14529","volume":"38","author":"R Helliwell","year":"2021","unstructured":"Helliwell R, Warnes H, Kietsiriroje N et al (2021) Body mass index, estimated glucose disposal rate and vascular complications in type 1 diabetes: beyond glycated haemoglobin. Diabet Med 38(5):e14529. https:\/\/doi.org\/10.1111\/dme.14529","journal-title":"Diabet Med"},{"issue":"3","key":"6273_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.diabet.2016.10.007","volume":"43","author":"V Gingras","year":"2017","unstructured":"Gingras V, Leroux C, Fortin A, Legault L, Rabasa-Lhoret R (2017) Predictors of cardiovascular risk among patients with type 1 diabetes: a critical analysis of the metabolic syndrome and its components. Diabetes Metab 43(3):217\u2013222. https:\/\/doi.org\/10.1016\/j.diabet.2016.10.007","journal-title":"Diabetes Metab"},{"key":"6273_CR13","unstructured":"Sciensano (2001) Initiative for Quality Improvement and Epidemiology in Diabetes (IQED). Available from https:\/\/www.sciensano.be\/en\/projects\/initiative-quality-improvement-and-epidemiology-diabetes. Accessed 21 Feb 2024"},{"issue":"8","key":"6273_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1089\/dia.2021.0003","volume":"23","author":"A Lavens","year":"2021","unstructured":"Lavens A, Nobels F, De Block C et al (2021) Effect of an integrated, multidisciplinary nationwide approach to type 1 diabetes care on metabolic outcomes: an observational real-world study. Diabetes Technol Ther 23(8):565\u2013576. https:\/\/doi.org\/10.1089\/dia.2021.0003","journal-title":"Diabetes Technol Ther"},{"issue":"25","key":"6273_CR15","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","year":"2002","unstructured":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25):3143\u20133421. https:\/\/doi.org\/10.1161\/circ.106.25.3143","journal-title":"Circulation"},{"issue":"16","key":"6273_CR16","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KGMM Alberti","year":"2009","unstructured":"Alberti KGMM, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640\u20131645. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.192644","journal-title":"Circulation"},{"key":"6273_CR17","unstructured":"International Diabetes Foundation (2006) The IDF consensus worldwide definition of the metabolic syndrome. Available from https:\/\/idf.org\/media\/uploads\/2023\/05\/attachments-30.pdf. Accessed 21 Dec 2023"},{"issue":"3","key":"6273_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/dom.13110","volume":"20","author":"T Nystr\u00f6m","year":"2018","unstructured":"Nystr\u00f6m T, Holzmann MJ, Eliasson B, Svensson A-M, Sartipy U (2018) Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. Diabetes Obes Metab 20(3):556\u2013563. https:\/\/doi.org\/10.1111\/dom.13110","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"6273_CR19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of LDL cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499\u2013502","journal-title":"Clin Chem"},{"issue":"1","key":"6273_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL et al (2020) ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"6273_CR21","doi-asserted-by":"publisher","first-page":"155217","DOI":"10.1016\/j.metabol.2022.155217","volume":"133","author":"C Boutari","year":"2022","unstructured":"Boutari C, Mantzoros CS (2022) A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism 133:155217. https:\/\/doi.org\/10.1016\/j.metabol.2022.155217","journal-title":"Metabolism"},{"issue":"3","key":"6273_CR22","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s13679-022-00477-x","volume":"11","author":"G Karamanakos","year":"2022","unstructured":"Karamanakos G, Kokkinos A, Dalamaga M, Liatis S (2022) Highlighting the role of obesity and insulin resistance in type 1 diabetes and its associated cardiometabolic complications. Curr Obes Rep 11(3):180\u2013202. https:\/\/doi.org\/10.1007\/s13679-022-00477-x","journal-title":"Curr Obes Rep"},{"key":"6273_CR23","unstructured":"Sciensano (2020) Weight status. Available from https:\/\/www.healthybelgium.be\/en\/health-status\/determinants-of-health\/weight-status. Accessed 21 Dec 2023"},{"issue":"11","key":"6273_CR24","doi-asserted-by":"publisher","first-page":"e1224","DOI":"10.1210\/clinem\/dgad302","volume":"108","author":"A Giandalia","year":"2023","unstructured":"Giandalia A, Russo GT, Ruggeri P et al (2023) The burden of obesity in type 1 diabetic subjects: a sex-specific analysis from the AMD Annals Initiative. J Clin Endocrinol Metab 108(11):e1224\u2013e1235. https:\/\/doi.org\/10.1210\/clinem\/dgad302","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6273_CR25","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1464-5491.2010.02956.x","volume":"27","author":"B Conway","year":"2010","unstructured":"Conway B, Miller RG, Costacou T et al (2010) Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med 27(4):398\u2013404. https:\/\/doi.org\/10.1111\/j.1464-5491.2010.02956.x","journal-title":"Diabet Med"},{"issue":"2","key":"6273_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1089\/dia.2018.0384","volume":"21","author":"NC Foster","year":"2019","unstructured":"Foster NC, Beck RW, Miller KM et al (2019) State of type 1 diabetes management and outcomes from the T1D Exchange in 2016\u20132018. Diabetes Technol Ther 21(2):66\u201372. https:\/\/doi.org\/10.1089\/dia.2018.0384","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"6273_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3803\/EnM.2022.101","volume":"37","author":"E-J Rhee","year":"2022","unstructured":"Rhee E-J (2022) The influence of obesity and metabolic health on vascular health. Endocrinol Metab 37(1):1\u20138. https:\/\/doi.org\/10.3803\/EnM.2022.101","journal-title":"Endocrinol Metab"},{"key":"6273_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13098-021-00641-8","volume":"13","author":"R Belete","year":"2021","unstructured":"Belete R, Ataro Z, Abdu A, Sheleme M (2021) Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr 13:25. https:\/\/doi.org\/10.1186\/s13098-021-00641-8","journal-title":"Diabetol Metab Syndr"},{"issue":"7","key":"6273_CR29","doi-asserted-by":"publisher","first-page":"100753","DOI":"10.1016\/j.jhepr.2023.100753","volume":"5","author":"J Mertens","year":"2023","unstructured":"Mertens J, Weyler J, Dirinck E et al (2023) Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes. JHEP Rep 5(7):100753. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100753","journal-title":"JHEP Rep"},{"issue":"7","key":"6273_CR30","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2337\/diacare.28.7.1649","volume":"28","author":"CEM De Block","year":"2005","unstructured":"De Block CEM, De Leeuw IH, Van Gaal LF (2005) Impact of overweight on chronic microvascular complications in type 1 diabetic patients. Diabetes Care 28(7):1649\u20131655. https:\/\/doi.org\/10.2337\/diacare.28.7.1649","journal-title":"Diabetes Care"},{"issue":"3","key":"6273_CR31","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3390\/ijms23031264","volume":"23","author":"R Herman","year":"2022","unstructured":"Herman R, Kravos NA, Jensterle M, Jane\u017e A, Dol\u017ean V (2022) Metformin and insulin resistance: a review of the underlying mechanisms behind changes in GLUT4-mediated glucose transport. Int J Mol Sci 23(3):1264. https:\/\/doi.org\/10.3390\/ijms23031264","journal-title":"Int J Mol Sci"},{"issue":"7","key":"6273_CR32","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.2337\/dc14-1140","volume":"37","author":"JL Chiang","year":"2014","unstructured":"Chiang JL, Kirkman MS, Laffel LMB, Peters AL, Type 1 Diabetes Sourcebook Authors (2014) Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 37(7):2034\u20132054. https:\/\/doi.org\/10.2337\/dc14-1140","journal-title":"Diabetes Care"},{"issue":"6","key":"6273_CR33","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/pharmaceutics14061180","volume":"14","author":"F Aberer","year":"2022","unstructured":"Aberer F, Pieber TR, Eckstein ML, Sourij H, Moser O (2022) Glucose-lowering therapy beyond insulin in type 1 diabetes: a narrative review on existing evidence from randomized controlled trials and clinical perspective. Pharmaceutics 14(6):1180. https:\/\/doi.org\/10.3390\/pharmaceutics14061180","journal-title":"Pharmaceutics"},{"issue":"10","key":"6273_CR34","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1111\/dom.12948","volume":"19","author":"F Staels","year":"2017","unstructured":"Staels F, Moyson C, Mathieu C (2017) Metformin as add-on to intensive insulin therapy in type 1 diabetes mellitus. Diabetes Obes Metab 19(10):1463\u20131467. https:\/\/doi.org\/10.1111\/dom.12948","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"6273_CR35","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S2213-8587(17)30194-8","volume":"5","author":"JR Petrie","year":"2017","unstructured":"Petrie JR, Chaturvedi N, Ford I et al (2017) Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5(8):597\u2013609. https:\/\/doi.org\/10.1016\/S2213-8587(17)30194-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6273_CR36","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.2147\/DMSO.S240903","volume":"16","author":"P Maffei","year":"2023","unstructured":"Maffei P, Bettini S, Busetto L, Dassie F (2023) SGLT2 inhibitors in the management of type 1 diabetes (T1D): an update on current evidence and recommendations. Diabetes Metab Syndr Obes 16:3579. https:\/\/doi.org\/10.2147\/DMSO.S240903","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"6273_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2337\/ds20-0038","volume":"34","author":"R Teng","year":"2021","unstructured":"Teng R, Kurian M, Close KL, Buse JB, Peters AL, Alexander CM (2021) Comparison of protocols to reduce diabetic ketoacidosis in patients with type 1 diabetes prescribed a sodium\u2013glucose cotransporter 2 inhibitor. Diabetes Spectr 34(1):42\u201351. https:\/\/doi.org\/10.2337\/ds20-0038","journal-title":"Diabetes Spectr"},{"issue":"12","key":"6273_CR38","doi-asserted-by":"publisher","first-page":"e1003461","DOI":"10.1371\/journal.pmed.1003461","volume":"17","author":"G Musso","year":"2020","unstructured":"Musso G, Sircana A, Saba F, Cassader M, Gambino R (2020) Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: a meta-analysis and meta-regression. PLoS Med 17(12):e1003461. https:\/\/doi.org\/10.1371\/journal.pmed.1003461","journal-title":"PLoS Med"},{"issue":"10","key":"6273_CR39","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1007\/s00125-023-05980-x","volume":"66","author":"C Mathieu","year":"2023","unstructured":"Mathieu C, Ahmadzai I (2023) Incretins beyond type 2 diabetes. Diabetologia 66(10):1809\u20131819. https:\/\/doi.org\/10.1007\/s00125-023-05980-x","journal-title":"Diabetologia"},{"issue":"10","key":"6273_CR40","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1681\/ASN.2007020199","volume":"18","author":"LA Stevens","year":"2007","unstructured":"Stevens LA, Coresh J, Feldman HI et al (2007) Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 18(10):2749\u20132757. https:\/\/doi.org\/10.1681\/ASN.2007020199","journal-title":"J Am Soc Nephrol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06273-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-024-06273-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06273-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T09:04:18Z","timestamp":1732784658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-024-06273-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6273"],"URL":"https:\/\/doi.org\/10.1007\/s00125-024-06273-7","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article is written on behalf of the IQED Group of Experts. The members of the IQED Group of Experts are L. Crenier, C. De Block, A.-S. Vanherwegen, A. Lavens, C. Mathieu, F. Nobels, J.-C. Philips, P. Oriot, M. Vandenbroucke and V. Vanelshocht. We would like to thank the staff of all Belgian specialised diabetes centres for the data collection.\u00a0Some of the data were presented as an abstract at the EASD meeting in 2023.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"Data cannot be shared publicly because of the use of pseudonymised person-level data. Readers who wish to access some or all of the data require approval from the Belgian Information Security Committee on Social Security and Health. More information about the access procedure may be obtained by contacting iqed@sciensano.be. Metadata (e.g. overview of variables, legal framework) are available on .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The IQED programme is funded by the Belgian National Institute for Health and Disability Insurance.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"AL, CM, PO and CDB developed the concept and design of this study. Data analysis was performed by AL. All authors made substantial contributions to the interpretation of results. AL, CDB, PO and CM drafted the manuscript, and all authors contributed to critical revision of the manuscript for important intellectual content. All authors approved the final manuscript for publication. AL had full access to the data and accepts the responsibility for the integrity of the data and accuracy of the data analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}